Evaluation of toxicity after one-months treatment with Bauhinia forficata decoction in streptozotocin-induced diabetic rats

BMC Complementary and Alternative Medicine

Iguatemy Lourenço Brunetti¹  Regina Célia Vendramini¹  Amanda Martins Baviera¹  Maria Teresa Pepato¹ 

[1] Department of Clinical Analyses, Araraquara School of Pharmacy, São Paulo State University (UNESP), Araraquara, SP, Brazil

关键词: extended treatment;    angiotensin-converting enzyme;    amylase;    creatine kinase;    bilirubin;    lactate dehydrogenase;    streptozotocin-diabetic rats;    serum enzymes;    Bauhinia forficata;   

Others  :  1234320
DOI  :  10.1186/1472-6882-4-7

 received in 2003-12-10, accepted in 2004-06-08,  发布年份 2004

【 摘 要 】

Background

Previous experiments have shown that a decoction of Bauhinia forficata leaves reduces the changes in carbohydrate and protein metabolism that occur in rats with streptozotocin-induced diabetes. In the present investigation, the serum activities of enzymes known to be reliable toxicity markers were monitored in normal and streptozotocin-diabetic rats to discover whether the use of B. forficata decoction has toxic effects on liver, muscle or pancreas tissue or on renal microcirculation.

Methods

An experimental group of normal and streptozotocin-diabetic rats received an aqueous decoction of fresh B. forficata leaves (150 g/L) by mouth for 33 days while a control group of normal and diabetic rats received water for the same length of time. The serum activity of the toxicity markers lactate dehydrogenase, creatine kinase, amylase, angiotensin-converting enzyme and bilirubin were assayed before receiving B. forficata decoction and on day 19 and 33 of treatment.

Results

The toxicity markers in normal and diabetic rats were not altered by the diabetes itself nor by treatment with decoction. Whether or not they received B. forficata decoction the normal rats showed a significant increase in serum amylase activity during the experimental period while there was a tendency for the diabetic rats, both treated and untreated with decoction, to have lower serum amylase activities than the normal rats.

Conclusions

Administration of an aqueous decoction of B. forficata is a potential treatment for diabetes and does not produce toxic effects measurable with the enzyme markers used in our study.

【 授权许可】

   
2004 Pepato et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Viana EP, Santa-Rosa RS, Almeida SSMS, Santos LS: Constituents of the stem bark of Baunhinia guianensi. Fitoterapia 1999, 70:111-211.
• [2]Miyake ET, Akisue G, Akisue MK: Pharmacognostic characterization of pata de vaca Bauhinia forficata. Rev Bras Farmacog 1986, 1:58-68.
• [3]Donato AM: Anatomia foliar e abordagem fitoquímica de Baunhinia forficata link. Bradea 1995, 6:357-371.
• [4]Pepato MT, Keller AM, Baviera AM, Kettelhut IC, Vendramini RC, Brunetti IL: Anti-diabetic activity of Baunhinia forficata decoction in streptozotocin-diabetic rats. J Ethnopharmacol 2002, 81:191-197.
• [5]Lapa AJ, Souccar C, Lina-Landman MTR, Godinho RO, Lima TCM: Farmacologia e toxicologia de produtos naturais. In In Farmacognosia: da planta ao medicamento. 4th edition. Edited by Simões CMO. Porto Alegre/Florianópolis: Ed. UFRGS/UFSC; 2002:183-198.
• [6]Matos FJA: Plantas medicinais-Guia de seleção e emprego de plantas usadas em fitoterapia nordeste of Brazil. 2nd edition. Fortaleza: Imprensa Universitária-UFC; 2000.
• [7]Rules of Brazilian Ethic Committees [http://www.cobea.org.br/etica.htm#3] webcite
• [8]Duboswski KM: An ortho-toluidine method for body fluid glucose determination. Clin Chem 1962, 8:215-235.
• [9]Bolleter WT, Bushman CJ, Tidwell PW: Spectrophotometric determination of ammonia as indophenol. Anal Chem 1961, 33:592-594.
• [10]Bergemeyer HU: Methods of enzymatic analysis. Volume 9. Florida:VCH; 1985::157.
• [11]Whitaker JE: A general colorimetric produced for the estimation of enzymes which are linked the NADH-NAD System. Clin Chim Acta 1969, 24:23-27.
• [12]Caraway WT: A stable starch substrate for the determination of amylase in serum and other body fluids. Am J Clin Path 1959, 32:97-99.
• [13]Malloy H, Evelyn KA: The determination of bilirubin with the photoelectric colorimeter. J Biol Chem 1937, 119:481-490.
• [14]Sims FH, Horn C: Some observations powell's method for the determination of serum bilirubin. Am J Clin 1958, 29:412-417.
• [15]Committee on Enzymes Scandinavian Society for Clinical Chemistry and Clinical Physiology: Recommended method for the determination of creatine kinase in blood. J Clin Lab Invest 1976, 36:711-723.
• [16]Groof JL, Harp JB, DiGirolano M: Simplified enzymatic assay of angiotensin-converting enzyme in serum. Clin Chem 1993, 39:400-404.
• [17]Aldrich JE: Clinical enzymology. In In Clinical chemistry: concepts and applications. Edited by Anderson SC, Cockayne S. New York: McGraw-Hill; 2003:261-284.
• [18]Ingram LR: Liver function. In In Clinical chemistry: concepts and applications. Edited by Anderson SC, Cockayne S. New York: McGraw-Hill; 2003:285-321.
• [19]Mori MD, Baviera AM, Ramalho LTO, Vendramini RC, Brunetti IL, Pepato MT: Temporal response pattern of biochemical analytes in experimental diabetes. Biotechnol Appl Biochem 2003, 38:183-191.
• [20]Stanely P, Prince M, Menon VP: Hypoglycaemic and other related actions of Tinospora cordiofolia roots in alloxan-induced diabetic rats. J Ethnopharmacol 2000, 70:9-15.
• [21]Mansour HA, Newairy AS, Yousef MI, Sheiweits SA: Biochemical study of the effects of some Egyptian herbs in alloxan-induced diabetic rats. Toxicology 2002, 170:221-228.
• [22]Scott FW, Trick KD, Lee LP, Hynie HM, Heick HMC, Nera E: Serum enzymes in the BB rat before and after onset of the overt diabetic syndrome. Clin Chem 1984, 17:270-275.
• [23]Lazarov G, Danev S, Manolov D, Dobrey S: Creatine kinase in patients with diabetes mellitus. Vutr Bolesv 1990, 29:77-83.
• [24]Zhao X, Bassirat M, Zeinab K, Helme RD: Effects of diabetes on creatine kinase activity in streptozotocin diabetic rats. Chin Med 1999, 112:1028-1031.
• [25]Al-Shabanah AO, El-Kashef HA, Badary AO, Bekairi AM, Elmazar MM: Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinectics and acute cardiotoxicity of doxorubicin in rats. Pharmacol Res 2000, 41:31-37.
• [26]Barneo L, Esteban MM, Garcia-Pravia C, Diaz F, Marin B: Islet transplatation restores normal serum amylase levels in diabetic rats. Eur Surg Res 1990, 22:143-150.
• [27]Hegyi P, Takács T, Tiszlavicz L, Czako L, Lonovics J: Recovery of exocrine pancreas six months following pancreatitis indution with L-arginine in STZ-diabetic rats. J Physiol 2000, 94:51-55.
• [28]Majumdar AP, Dubick MA: Gastrin affects enzymes activity and gene expression in the aging rat pâncreas. Exp Gerontol 1991, 26:57-64.
• [29]Ishibashi T, Matsumoto S, Harada H, Ochi K, Tanaka J, Seno T, Oka H, Miyake H, Kimura I: Aging and exocrine pancreatic function evaluated by recently standardized secretion test. Nippon Ronen Igakkai Zasshi 1991, 28:599-605.
• [30]Koller MM, Maeda N, Purushotham KR, Scarpace PJ, Humphreys-Baher MG: A biochemical analysis of parotid and submandibular salivary gland function with age after simultaneous stimulation with pilocarpine and isoproterenol in female NIA Fischer 344 rats. Arch Oral Biol 1992, 37:219-230.
• [31]Kim SK, Cuzzort LM, McKean RK: Amylase mRNA synthesis and ageing in rat parotid glands following isoproterenol-stimulated secretion. Arch Oral Biol 1992, 37:349-354.
• [32]Sawhney AK, Lott JA: Angiotensin-converting enzyme (ACE). In In Clinical enzymology: a case oriented approach. Edited by Lott JA, Wolf PL. New York: Field, Rich and Associates Inc; 1986:95-110.
• [33]Ustundag B, Cay M, Naziroglu M, Dilsiz N, Cabre MJC, Ilhan N: The study of renin-aldosterone in experimental Diabetes Mellitus. Cell Biochem Function 1999, 17:193-198.
• [34]Anderson S, Jung F, Ingelfinger J: Renal renin-angiotensin system in the diabetes: functional immunohistochemical, and molecular biological correlations. J Am Physiol Soc 1993, 34:477-486.
• [35]Leehey DJ, Singh AK, Alavi N, Singh R: Role of angiotensin II in diabetic nephropathy. Kidney Int Supl 2000, 77:93-98.
• [36]Mizuiri S, Kobayashi M, Nakanishi T: Renal angiotensin-converting enzyme localization in diabetic rats and the effect of low protein diet. Nephron 1997, 76:186-191.
• [37]Ustung B, Canatan H, Cinkilinc N, Halifeoglu I, Bahcecioglu IH: Angiotensin converting enzyme (ACE) activity levels in insulin independent diabetes mellitus and effect of ACE levels on the diabetic patients with nephropathy. Cell Biochem Funct 2000, 18:23-28.
• [38]Toop MJ, Dallinger KJ, Jennings PE, Barnett AH: Angiotensin-converting enzyme (ACE): relationship to insulin dependent diabetes and microangiopaty. Diabetic Med 1986, 3:455-457.
• [39]Lierberman J, Sastre A: Serum angiotensin-converting enzyme: elevation in diabetic mellitus. Ann Int Med 1980, 93:825-826.
• [40]Garg SK, Makkar HP, Nagal KB, Sharma SK, Wadhwa DR, Singh B: Oak (Quercus incana) leaf poisoning in cattle. Vet Hum Toxicol 1992, 34:161-164.